Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced record-breaking financial results for 2024, driven by robust sales of their flagship product WAKIX® (pitolisant). The company reported $714.7 …
Harmony Biosciences Reports Record 2024 Revenue, Targets Billion-Dollar Milestone in 2025 Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File (RTF) letter for its supplemental …
Harmony Biosciences Faces Regulatory Setback, Outlines Future Plans for Pitolisant Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced robust preliminary net product revenues for the fourth quarter and full year of 2024, with figures reaching $201 million …
Harmony Biosciences Reports Strong Revenue Growth and Outlines Ambitious 2025 Strategy Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced a remarkable achievement with $186.0 million in net revenue for the third quarter ending September 30, 2024. This milestone …
Harmony Biosciences Reports Record Revenue and Plans Expansion in CNS Treatments Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is set to showcase its promising late-stage pipeline during an Investor Day event scheduled for October 1 in New York City. …
Harmony Biosciences to Unveil Promising Late-Stage Pipeline at Investor Day Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported a 29% increase in net revenue for the quarter ended June 30, 2024. The company highlighted progress in its …
Harmony Biosciences Reports Q2 Growth and Expands Pipeline Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) recently denied a Citizen Petition filed by a short seller. The …
FDA Denies Petition Challenging Safety and Efficacy of Harmony Biosciences’ Drug Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets. The …
FDA Approves Harmony Biosciences’ WAKIX for Pediatric Narcolepsy Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) recently unveiled promising data at the annual meeting of the Associated Professional Sleep Societies, “SLEEP 2024.” The data from a Phase 2 …
Harmony Biosciences Presents Promising Data on Pitolisant for Myotonic Dystrophy Type 1 Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) announced its recent acquisition of Epygenix Therapeutics, Inc., marking a significant step into the rare epilepsy sector. This acquisition not only broadens …
Harmony Biosciences Expands into Rare Epilepsy Market with Epygenix Therapeutics Acquisition Read More